Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease

20073,245 citationsJournal Articlebronze Open Access

Authors

Peter Calverley · Aintree University Hospital

Julie A. Anderson · GlaxoSmithKline (United Kingdom)

Bartolomé R. Celli · St. Elizabeth's Medical Center

Gary T. Ferguson · Pulmonary Associates

Christine Jenkins · Woolcock Institute of Medical Research

Paul Jones · St George's, University of London

Julie Yates

Abstract

The reduction in death from all causes among patients with COPD in the combination-therapy group did not reach the predetermined level of statistical significance. There were significant benefits in all other outcomes among these patients. (ClinicalTrials.gov number, NCT00268216 [ClinicalTrials.gov].).

Topics & Keywords

Chronic Obstructive Pulmonary Disease (COPD) Research Respiratory Support and Mechanisms Asthma and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 356, Issue 8, pp. 775-789

DOI: 10.1056/nejmoa063070

Field-Weighted Citation Impact: 206.90